Web13 apr. 2024 · THURSDAY, April 13, 2024 (HealthDay News) -- The addition of metastasis-directed therapy (MDT), consisting of definitive radiation therapy to all sites of disease, to hormone therapy results in improved progression-free survival for men with oligometastatic prostate cancer, according to a study published online April 6 in JAMA Oncology. WebHormone therapy is often given together with radiation therapy for localized disease (note: it is also used alone or in combination with other treatments for men with metastatic …
Metastasis-Directed Radiation Therapy Plus Hormone Therapy …
WebProstate cancer cells need androgens to grow. Reducing the amount of androgens in the body or blocking prostate cancer cells from using them can help treat prostate cancer. This therapy does not cure the cancer, but it can help control it. It may be used alone. Or it may be used with radiation therapy to help make this treatment more effective. Web13 apr. 2024 · The use of metastasis-directed radiotherapy plus hormone therapy improved progression-free survival (PFS) compared with hormone therpy alone in patients with … drug schedules bc canada
Treatment options Cancer Australia
WebPotential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Abstract: In 2012, prostate cancer will once again be the second-leading cause of cancer death of American males. Although initially treatable, prostate cancer can recur in a hormone refractory form that is not responsive to current available therapies. Web21 uur geleden · This randomized trial of intermittent androgen deprivation therapy with or without radiation therapy to up to 5 sites of oligometastatic disease from prostate … Web14 apr. 2024 · The use of metastasis-directed radiotherapy plus hormone therapy improved progression-free survival (PFS) compared with hormone therapy alone in patients with oligometastatic prostate cancer, according to findings from the phase 2 EXTEND trial (NCT03599765). 1 combine multiple tabs into one in excel